Chimerix Inc (NASDAQ:CMRX) saw unusually-high trading volume on Wednesday . Approximately 1,620,901 shares were traded during mid-day trading, an increase of 423% from the previous session’s volume of 309,826 shares.The stock last traded at $4.61 and had previously closed at $4.58.

CMRX has been the topic of a number of research reports. Zacks Investment Research raised shares of Chimerix from a “hold” rating to a “buy” rating and set a $5.25 target price on the stock in a research note on Friday, November 10th. ValuEngine raised shares of Chimerix from a “strong sell” rating to a “sell” rating in a research note on Wednesday, October 11th.

The stock has a market capitalization of $211.60, a price-to-earnings ratio of -3.21 and a beta of 1.46.

Chimerix (NASDAQ:CMRX) last posted its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.43) by $0.06. Chimerix had a negative net margin of 1,440.67% and a negative return on equity of 26.00%. The firm had revenue of $0.90 million during the quarter, compared to the consensus estimate of $0.81 million. research analysts expect that Chimerix Inc will post -1.6 EPS for the current year.

In other Chimerix news, insider Linda M. Richardson sold 19,833 shares of the business’s stock in a transaction on Friday, December 1st. The shares were sold at an average price of $4.47, for a total value of $88,653.51. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 4.40% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in CMRX. Voya Investment Management LLC lifted its position in Chimerix by 18.3% in the second quarter. Voya Investment Management LLC now owns 29,203 shares of the biopharmaceutical company’s stock valued at $159,000 after acquiring an additional 4,526 shares during the last quarter. State of Wisconsin Investment Board purchased a new stake in Chimerix in the second quarter valued at $185,000. The Manufacturers Life Insurance Company lifted its position in Chimerix by 8.3% in the second quarter. The Manufacturers Life Insurance Company now owns 39,628 shares of the biopharmaceutical company’s stock valued at $216,000 after acquiring an additional 3,042 shares during the last quarter. Metropolitan Life Insurance Co. NY purchased a new stake in Chimerix in the first quarter valued at $226,000. Finally, Alps Advisors Inc. lifted its position in Chimerix by 5.5% in the second quarter. Alps Advisors Inc. now owns 42,023 shares of the biopharmaceutical company’s stock valued at $229,000 after acquiring an additional 2,178 shares during the last quarter. 70.32% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: This piece was reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this piece on another domain, it was stolen and reposted in violation of US and international copyright and trademark law. The original version of this piece can be accessed at https://theolympiareport.com/2017/12/27/chimerix-cmrx-sees-strong-trading-volume.html.

Chimerix Company Profile

Chimerix, Inc is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses, including smallpox, adenoviruses (AdV), and the human herpesviruses.

Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with Analyst Ratings Network's FREE daily email newsletter.